title: Response to comments on Zhang et al. Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care 2014;37:1338-1345.
authors.affiliation: Graduate Program in Operations Research, North Carolina State University, Raleigh, NC.
authors.forename: Yuanhui
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Division of Endocrinology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
authors.forename: Rozalina G
authors.initials: RG
authors.lastname: McCoy
authors.affiliation: Department of Public Health Sciences, University of Virginia, Charlottesville, VA.
authors.forename: Jennifer E
authors.initials: JE
authors.lastname: Mason
authors.affiliation: Division of Endocrinology, Department of Internal Medicine, Mayo Clinic, Rochester, MN Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
authors.forename: Steven A
authors.initials: SA
authors.lastname: Smith
authors.affiliation: Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN Optum Labs, Cambridge, MA.
authors.forename: Nilay D
authors.initials: ND
authors.lastname: Shah
authors.affiliation: Department of Industrial and Operations Engineering, University of Michigan, Ann Arbor, MI btdenton@umich.edu.
authors.forename: Brian T
authors.initials: BT
authors.lastname: Denton
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male
chemical_list: D007004:Hypoglycemic Agents